References
- 1. Güzey S, Aykan A, Avşar S, Yavan İ, Öztürk S. Recurrent Breast Cancer with Cutaneous Metastasis in the Late Term. Turkish Journal of Plastic Surgery. 2017;25(1):34+. DOI: 10.5152/TurkJPlast-Surg.2016.1980
- 2. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. Ca Cancer J Clin. 2017;67(1):7-30. DOI: 10.3322/caac.2138710.3322/caac.21387
- 3. Cancer UK. Breast cancer symptoms. 2010.
- 4. McGuire, S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Advances in Nutrition: An International Review Journal. 2016;7(2):418-9. DOI: 10.3945/an.116.01221110.3945/an.116.012211
- 5. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. Ca Cancer J Clin. 2016;66(2):115-32. DOI: 10.3322/caac.2133810.3322/caac.21338
- 6. Zhao X, Qu J, Sun Y, Wang J, Liu X, Wang F, et al. Prognostic significance of tumor-associated macrophages in breast cancer: a meta-analysis of the literature. Onco-target. 2017;8(18):30576-86. DOI: 10.18632/oncotarget.1573610.18632/oncotarget.15736
- 7. Robson ME, Chappuis PO, Jaya S, Nora W, Jeff B, Goffin JR, et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 2003;6(1):R8. DOI: 10.1186/bcr65810.1186/bcr658
- 8. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama. 2017 Jun 20;317(23):2402-16.
- 9. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36(10):1200-8. DOI: 10.1016/S0959-8049(00)00110-610.1016/S0959-8049(00)00110-6
- 10. Liu X, Ma Y, Yang W, Wu X, Jiang L, Chen X. Identification of therapeutic targets for breast cancer using biological informatics methods. Mol Med Rep. 2015;12(2):1789. DOI: 10.3892/mmr.2015.356510.3892/mmr.2015.3565446409025824986
- 11. Zhao Y, Bing F. Screening of biomarkers for prediction of response to and prognosis after chemotherapy for breast cancers. Onco Targets Ther. 2016;9(Issue 1):2593-600. DOI: 10.2147/OTT.S9235010.2147/OTT.S92350486100127217777
- 12. Wu D, Han B, Guo L, Fan Z. Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis. J Obstetrics & Gynaecology. 2016;36(5):615-21. DOI: 10.3109/01443615.2015.112790210.3109/01443615.2015.112790226804550
- 13. Athar A, Fullgrabe A, George N, Iqbal H, Huerta L, Ali A, et al. ArrayExpress update - from bulk to single-cell expression data. Nucleic acids res. 2019 Jan 8;47(D1):D711-d5. DOI: 10.1093/nar/gky96410.1093/nar/gky964632392930357387
- 14. Carvalho BS, Irizarry RA. A framework for oligonucleotide microarray preprocessing. Bioinformatics. 2010;26(19):2363-7. DOI: 10.1093/bioinformatics/btq43110.1093/bioinformatics/btq431294419620688976
- 15. Smyth GK. limma: Linear Models for Microarray Data. Bioinformatics & Computational Biology Solutions Using R & Bioconductor. 2011:397-420. DOI: 10.1007/0-387-29362-0_2310.1007/0-387-29362-0_23
- 16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50. DOI: 10.1073/pnas.050658010210.1073/pnas.0506580102123989616199517
- 17. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000 Jan 1;28(1):27-30. DOI: 10.1093/nar/28.1.2710.1093/nar/28.1.2710240910592173
- 18. Shannon, P. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003;13(11):2498. DOI: 10.1101/gr.123930310.1101/gr.123930340376914597658
- 19. Therneau TM, Grambsch PM, Modeling Survival Data: Extending The Cox Model. 2000. DOI: 10.1007/978-1-4757-3294-810.1007/978-1-4757-3294-8
- 20. Fromont-Racine M, Rain JC, Legrain P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat Genet. 1997 Jul;16(3):277-82. DOI: 10.1038/ng0797-27710.1038/ng0797-2779207794
- 21. Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, et al. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. Oncotarget. 2017;8(2):2423-36. DOI: 10.18632/oncotarget.1368210.18632/oncotarget.13682535681227911856
- 22. Xie N, Yao Y, Wan L, Zhu T, Liu L, Yuan J. Next-generation sequencing reveals lymph node metastasis associated genetic markers in colorectal cancer. Exp Ther Med. 2017;14(1):338-43. DOI: 10.3892/etm.2017.446410.3892/etm.2017.4464548863128672935
- 23. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res. 2018;24(11):2482-90. DOI: 10.1158/1078-0432.CCR-17-307010.1158/1078-0432.CCR-17-307029420223
- 24. Sotgia F, Lisanti MP. Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget. 2017;8(40):68095-107. DOI: 10.18632/onco-target.19677
- 25. Liu X-H, Kirschenbaum A, Yao S, Stearns ME, Holland JF, Claffey K, et al. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin exp metastasis. 1999;17(8):687-94. DOI: 10.1023/A:100672811954910.1023/A:1006728119549
- 26. Dossus L, Kaaks R, Canzian F, Albanes D, Berndt SI, Boeing H, et al. PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010;31(3):455-61. DOI: 10.1093/carcin/bgp30710.1093/carcin/bgp307
- 27. Festa-Vasconcellos JS, Piranda DN, Amaral LM, Indio-do-Brasil V, Koifman S, Vianna-Jorge R. Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: association between PTGS2 haplotypes and histopathological features. Breast cancer res treat. 2012;132(1):251-8. DOI: 10.1007/s10549-011-1828-010.1007/s10549-011-1828-0
- 28. De CP, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, et al. COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients. Anticancer Res. 2018;38(3):1485. DOI: 10.21873/anticanres.1237510.21873/anticanres.12375
- 29. Goswami BB, Michael K, Diana N, Cebula TA. Apoptosis induced by a cytopathic hepatitis A virus is dependent on caspase activation following ribosomal RNA degradation but occurs in the absence of 2’-5’ oligoadenylate synthetase. Antiviral Res. 2004;63(3):153-66. DOI: 10.1016/j.antiviral.2004.02.00410.1016/j.antiviral.2004.02.004
- 30. Kocic G, Jevtovic T, Pavlovic D, Bjelakovic G, Kocic R. 290 A role of IFN-α in the double-stranded RNA degradation during Fas-ligand induced liver apoptosis and balance between proliferation and death. J Hepatol. 2006;44(06):S113-S. DOI: 10.1016/S0168-8278(06)80291-610.1016/S0168-8278(06)80291-6
- 31. Koedoot E, Dévédec SL, Water BVD. Abstract 893: Systematic assessment of spliceosome components as drivers of breast cancer progression. Cancer Res. 2017;77(13 Supplement):893. DOI: 10.1158/1538-7445.AM2017-89310.1158/1538-7445.AM2017-893
- 32. Quidville V, Alsafadi S, Goubar A, Commo F, Scott V, Pioche-Durieu C, et al. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy. Cancer Res. 2013;73(7):2247-58. DOI: 10.1158/0008-5472.CAN-12-250110.1158/0008-5472.CAN-12-250123358685
- 33. Soto-Guzman A, Villegas-Comonfort S, Cortes-Reynosa P, Salazar EP. Role of arachidonic acid metabolism in Stat5 activation induced by oleic acid in MDA-MB-231 breast cancer cells. Prostaglandins Leukotrienes & Essential Fatty Acids. 2013;88(3):243-9. DOI: 10.1016/j. plefa.2012.12.003
- 34. Wang Z, Wang N, Han S, Wang D, Mo S, Yu L, et al. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. Plos One. 2013;8(7):e68566. DOI: 10.1371/journal.pone.006856610.1371/journal.pone.0068566370261423861918
- 35. Chun-Te C, Yi D, Hirohito Y, Jung-Mao H, Hsu-Ping K, Hortobagyi GN, et al. Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer. Mol Cancer Ther. 2012;11(10):2212-21. DOI: 10.1158/1535-7163. MCT-12-0180